scFv(CD38)-41BB-CD3zeta CAR-T Lentivirus

The scFv (CD38)-41BB-CD3zeta CAR-T lentivirus is an innovative therapeutic approach designed to treat various malignancies, particularly those associated with CD38-positive tumors, such as multiple myeloma. CAR-T cell therapy has become a groundbreaking cancer treatment, harnessing the patient''s own immune system to target and eliminate cancer cells. This specialized construct combines the unique properties of a single-chain variable fragment (scFv), a costimulatory domain, and a signaling motif to enhance T cell efficacy against tumor cells. Central to this CAR (chimeric antigen receptor) design is the scFv targeting CD38. CD38 is a transmembrane glycoprotein overexpressed in various hematologic malignancies, making it an attractive target for immunotherapy. The scFv enables T cells to recognize and bind to CD38 expressed on the surface of malignant cells, thereby initiating an immune response. By using the scFv fragment, CAR-T cells can specifically target these cancer cells while minimizing off-target effects.

The inclusion of the 41BB (also known as CD137) costimulatory domain is crucial for enhancing T cell activation and persistence. 41BB signaling promotes T cell survival, proliferation, and function, especially in inflammatory environments. This co-stimulatory signal works synergistically with T cell receptor signals from the CD3zeta domain, which plays a crucial role in initiating cytotoxic responses. The CD3zeta chain provides the necessary signaling cascade, leading to T cell activation, cytokine production, and subsequent tumor cell destruction. The lentiviral vector used to deliver this CAR construct is able to stably integrate into the T cell genome. This is a significant advantage because it enables long-term expression of the CAR, ensuring that the modified T cells can continue to recognize and eliminate malignant cells for a longer period of time. In addition, lentiviral vectors can transduce both dividing and non-dividing cells, thereby improving the production efficiency of CAR-T cells.